Refine by
Cancer Cell Articles & Analysis: This-Month
1 articles found
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials. These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 billion, abandoned drugs represent an opportunity to bring drugs to ...